As of 2024-12-12, the EV/EBITDA ratio of Intellia Therapeutics Inc (NTLA) is -1.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NTLA's latest enterprise value is 1,311.78 mil USD. NTLA's TTM EBITDA according to its financial statements is -903.02 mil USD. Dividing these 2 quantities gives us the above NTLA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.5x - 16.5x | 15.0x |
| Forward P/E multiples | 15.8x - 18.5x | 16.3x |
| Fair Price | (139.09) - (145.14) | (137.72) |
| Upside | -1086.5% - -1129.4% | -1076.7% |
| Date | EV/EBITDA |
| 2024-12-11 | -1.45 |
| 2024-12-10 | -1.52 |
| 2024-12-09 | -1.51 |
| 2024-12-06 | -1.52 |
| 2024-12-05 | -1.40 |
| 2024-12-04 | -1.50 |
| 2024-12-03 | -1.51 |
| 2024-12-02 | -1.64 |
| 2024-11-29 | -1.62 |
| 2024-11-27 | -1.58 |
| 2024-11-26 | -1.52 |
| 2024-11-25 | -1.53 |
| 2024-11-22 | -1.48 |
| 2024-11-21 | -1.42 |
| 2024-11-20 | -1.34 |
| 2024-11-19 | -1.46 |
| 2024-11-18 | -1.46 |
| 2024-11-15 | -1.44 |
| 2024-11-14 | -1.57 |
| 2024-11-13 | -1.68 |
| 2024-11-12 | -1.74 |
| 2024-11-11 | -1.84 |
| 2024-11-08 | -1.75 |
| 2024-11-07 | -1.67 |
| 2024-11-06 | -1.67 |
| 2024-11-05 | -1.60 |
| 2024-11-04 | -1.57 |
| 2024-11-01 | -1.53 |
| 2024-10-31 | -1.47 |
| 2024-10-30 | -1.48 |
| 2024-10-29 | -1.55 |
| 2024-10-28 | -1.70 |
| 2024-10-25 | -1.66 |
| 2024-10-24 | -1.65 |
| 2024-10-23 | -2.11 |
| 2024-10-22 | -2.24 |
| 2024-10-21 | -2.19 |
| 2024-10-18 | -2.24 |
| 2024-10-17 | -2.23 |
| 2024-10-16 | -2.18 |
| 2024-10-15 | -2.06 |
| 2024-10-14 | -2.06 |
| 2024-10-11 | -1.96 |
| 2024-10-10 | -1.87 |
| 2024-10-09 | -1.85 |
| 2024-10-08 | -1.88 |
| 2024-10-07 | -1.87 |
| 2024-10-04 | -1.89 |
| 2024-10-03 | -1.85 |
| 2024-10-02 | -1.95 |